NYSE-listed pharma major Abbott Labs has inked a deal with Piramal Healthcare to acquire Piramal’s Healthcare Solutions business. Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramal’s Healthcare Solutions Business. May 21, am. N) will pay $ billion to acquire the branded generics business of Piramal’s healthcare solutions accounted for about 55 percent of its.
|Published (Last):||10 July 2004|
|PDF File Size:||14.9 Mb|
|ePub File Size:||11.71 Mb|
|Price:||Free* [*Free Regsitration Required]|
Jude Medical set to close. Warmuth, senior vice-president at the established products division of Abbott, told Mint on Friday. Facts, background information, dossiers.
The Healthcare Solutions business will operate as a separate business unit, reporting into Abbott’s newly-created Established Products Division EPDwhich was formed to focus on branded generics, maximizing the opportunity in emerging markets. It is paying roughly 8. In fact, 10 days before the Piramal acquisition, Abbott announced a licensing and supply deal with Indian pharmaceutical company Zydus Cadila.
Abbott to pay $ billion for unit of India’s Piramal | Reuters
The business that will continue to be under Piramal include custom manufacturing for third parties, critical care, over the counter consumer products, manufacture and supply of active pharmaceutical ingredients APIvitamin and fine chemicals, diagnostic medical devices and equipment and dignostic services and clinical resreach services.
Increased funding expands the scope for drug research, but that alone is not enough; other pieces have to fall in place, Piramal notes.
My watch list my. Disagreements over valuation have prevented more deals from getting done. Abbott said it was advised by Morgan Stanley, while Piramal said it did not have priamal financial advisor on the deal. All the same, the West continues to dominate pharmaceutical innovation, and companies in India and other emerging markets could play a supportive role, according to Danzon.
Abbott buys Piramal’s Healthcare Solutions
But new Wharton research provides better insight into the benefits of PE buyouts. The upfront payment is scheduled to be made by Acquisitiln, with the annual payments starting in Fujifilm Diosynth Biotechnologies Announces Strategic Alliance with Piramal Healthcare for Production of Antibody Drug Conjugates Fujifilm Diosynth Biotechnologies has announced it has entered into a strategic alliance with Piramal Healthcare UK Ltd, whereby the two parties will offer the seamless contract development and manufacture of antibody drug conjugates ADCsa growing niche in the development of biopharmace Piramal justified the sale by saying that future value from the branded generics business would come from business growth outside India.
The combined Abbott and Piramal sales force will be the largest in India, Warmuth said, adding that the price that it paid for the Indian business was liramal right. More news by Piramal Healthcare. Microsoft Internet Explorer 6. Abbott has completed its acquisition of Piramal’s Healthcare Solutions business.
A ‘Bigger Foothold’: What Does the Abbott-Piramal Deal Mean for Indian Pharma?
Piramal’s Healthcare Solutions business has a comprehensive portfolio of branded generics, including market-leading brands in multiple therapeutic areas, including antibiotics, respiratory, cardiovascular, pain and neuroscience. India certainly offers a large and growing domestic market with rising incomes and increasing health insurance coverage, says Danzon.
Abbott will pay Healtucare per share. The business will continue to be led by its current India-based management team. Please login to the form below.
To use all the functions on Solutioms. By comparison, Cipla trades at about 4. Since then, further pharmaceutical deals have been expected, as global majors search for growth and low-cost production of generics, as patents on major branded drugs are set to expire. Over the past ten years, Abbott has established a leading presence in emerging markets and now more than 20 per cent of the company’s total sales are generated in these growing economies.
Piramal started the pharma business in and has expanded it through organic and inorganic growth. Fujifilm Diosynth Biotechnologies has announced it has entered into a strategic alliance with Piramal Healthcare UK Ltd, whereby the two parties will offer the seamless contract development and manufacture of antibody drug conjugates ADCsa growing niche in the development of biopharmace Related Videos ET Now: Sign up for the weekly Knowledge Wharton e-mail newsletter, offering business leaders cutting-edge research and ideas from Wharton faculty and other experts.
Expensive legal battles with patent holders, higher regulatory scrutiny after charges of poor manufacturing quality, and increased competition in the generics space have compelled Indian pharmaceuticals firms to look for buyers.
To use all functions of this page, please activate cookies in your browser. It allows Abbott to commercialize two dozen Zydus Cadila drugs in 15 emerging markets. These other players are not even interested in doing that. Wharton professor of healthcare management Patricia Danzon agrees. Ot to Wharton faculty and industry experts, changing global business models and the resources needed to develop blockbuster drugs are soolutions Indian companies to join forces with multinationals through strategic alliances or as targets for acquisitions.
It makes a lot of sense if they can pull off all the integration issues.